Glad to see a nice healthy pull back. Sold 30 k shares for 3.60 yesterday and bought it all back at 3.17 today.
See you on the bounce Monday!
Glad to see a nice healthy pull back. Sold 30 k shares for 3.60 yesterday and bought it all back at 3.17 today.
See you on the bounce Monday!
SP action looking like the build up to Jan 2021 spike to $8.50….. only difference is this time it
Feels a lot more warranted .
We’re still very undervalued here, hold the line, squeeze the shorts and watch this thing skyrocket .
Nasdaq
LXRX
Buy consensus
Analyst $7 ….12 month price target
I like this stock!
DD…. Over bought? SP $3.32, 1 year target avg $5.15….looks like we are still under valued by 35%, if you believe 1 year target will be fair value after earning call, could go either way but even 75% of 1 year target is $3.86
Overbought by technicals perhaps, but do your DD and you will see we were way over sold and undervalued.
The run up started about a week after the JPM Healthcare conference. What does that tell you? Tells me that the investors would met with Lexicon liked what they heard, believe the sales inflection is happening, and everyone who bailed in May 2023 is piling back in.
The volume we have seen in last few weeks is huge, I think we get well into the $4 range before the earning call and we will see from there, but the sales inflection is happening, to what degree we will soon see, but it’s hard to see Lexicon valued at less that a billion right now with the runway in front of it.
How does the recent RSO vesting impact share price, is that a factor in this run?
Where do we go from here given we are an inch from a 1 year high, up 142 % in a month, the short situation and what could be 3 more weeks til the earning call?
The 5 year chart makes this recent run look like it could unwind any time but this is a much different company and situation this time around, hype and risk is largely in the past and this is the real deal now, if not this earning call, by next we will undoubtably see a stock, price, skyrocketing, and in my honest opinion, but a certainty, not just a pump or hype.
Who has a crystal ball they could share a read out from what we could see in the next 2-3 weeks before the call.
When I look at the one year chart, as excited as I am to have seen this run the last few weeks, I realize the huge upside still yet to come.
We are just touching the SP zone of where we were at when they announced the FDA approval.
From there the shorts took us down hard but I don’t see that happening again as we have solid sales momentum and several key catalysts to take us much higher.
Do you research as I have, and you quickly realize this company is still way undervalued at only 714 million market cap . Should easily be a multi billion dollar company with the runway it has in front of it.
This is about to rip, selling anywhere near $3 is going to be looked back on as a mistake.
I’m sitting on 400k shares, not selling anything until Lexicon market cap is in the billions where it should be.
I’ve done my DD….
Great action today, after being up 22% yesterday only down right now 1.8, while Russell is down over 3%, and almost at avg daily volume at 11am
Shorts selling, institutions buying it right up, SP going up up up.
I like this stock
Still $.60 below May 2023, with a whole lotta risk take off the table and a sales inflection right in front of us
What’s driving this volume today???
Anyone thinking of selling before we hit double digits does not know the value of what they hold. Do your diligence.
Feels like they are holding back on PR these days , they don’t need it to hold SP up, huge institutional buying since JPM conf. Quarterly call will be huge, and I’ll be holding. So much growth to come I’m not selling anything til we hit double digits.
No reason Impefa can’t be the #1 HF med, 10x+ from here very possible
Ho hummm, nice recent price move but still $.20 below what the last round was raised at, $2.50.
Still very under valued , still time to get in if you have been sitting back watching.
$4-$4.50 after next earning call
Higher highs and higher lows on higher volume, we are on the move!
Anyone shorting Lexie is playing a game of chicken with a train head on, strong institutional buying going on into the earning call, guidance was and surely still is inflection coming by mid year. $4-5 by April. Buy out will come once we can show a path to $500 million in sales. If they wanted to drive sales we would see a euro partner, they are just looking to take this up to certain point.
Know what your holding
Next earning call guidance will send this soaring. This is a story of when , not if Impefa will be a major HF drug and will be bought out. Longs, hold the line, you will regret any profits taken this year, your shares will be worth way more in 2025!